Basic Information
| RNALocate ID: | RLID:01001685 |
| RNA Symbol: | hsa-miR-200b-3p |
| Localization: | Cytoplasm |
RNA Information
| RNA Name: | hsa-miR-200b |
| RNA ID: | miRBase:MIMAT0000318 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20864815 |
| Tissue/Cell Line: | Colon cancer cells |
| Method: | Microarray|Northern blot|RT-PCR |
| Description: | MicroRNAs such as let-7d, miR-19a, miR-19b and miR-200b, demonstrated nuclear localization at a level similar to that of cytoplasm. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001686 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
| RLID:11001571 | Exosome | Urine | 26576778 |
| RLID:11001572 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11001573 | Exosome | Brain tissue | 23382797 |
| RLID:11001574 | Exosome | Plasma | 23663360 |
| RLID:11001575 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000067 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
| RLID-D:11000341 | Microvesicle | Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-200b-3p | Splenic marginal zone lymphoma | MNDR-E-MI-26092 |
| MNDR | hsa-miR-200b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26093 |
| MNDR | hsa-miR-200b-3p | Tongue squamous cell carcinoma | MNDR-E-MI-26094 |
| MNDR | hsa-miR-200b-3p | Oral squamous cell carcinoma | MNDR-E-MI-26095 |
| MNDR | hsa-miR-200b-3p | Large cell neuroendocrine cancer | MNDR-E-MI-26096 |
| MNDR | hsa-miR-200b-3p | Medulloblastoma | MNDR-E-MI-26097 |
| MNDR | hsa-miR-200b-3p | Mucosa-associated lymphoid tissue lymphoma | MNDR-E-MI-26098 |
| MNDR | hsa-miR-200b-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26099 |
| MNDR | hsa-miR-200b-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26100 |
| MNDR | hsa-miR-200b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26101 |
| MNDR | hsa-miR-200b-3p | Lymphoma non-hodgkin | MNDR-E-MI-26102 |
| MNDR | hsa-miR-200b-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26103 |
| MNDR | hsa-miR-200b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26104 |
| MNDR | hsa-miR-200b-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26105 |
| MNDR | hsa-miR-200b-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26106 |
| MNDR | hsa-miR-200b-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26107 |
| MNDR | hsa-miR-200b-3p | Triple negative breast cancer | MNDR-E-MI-26108 |
| MNDR | hsa-miR-200b-3p | Breast cancer luminal | MNDR-E-MI-26109 |
| MNDR | hsa-miR-200b-3p | Androgen-independent prostate cancer | MNDR-E-MI-26110 |
| MNDR | hsa-miR-200b-3p | Gastric cancer | MNDR-E-MI-26111 |
| MNDR | hsa-miR-200b-3p | Gastric lymphoma | MNDR-E-MI-26112 |
| MNDR | hsa-miR-200b-3p | Alzheimer disease | MNDR-E-MI-26113 |
| MNDR | hsa-miR-200b-3p | Bladder cancer | MNDR-E-MI-26114 |
| MNDR | hsa-miR-200b-3p | Head and neck cancer | MNDR-E-MI-26115 |
| MNDR | hsa-miR-200b-3p | Ataxia telangiectasia | MNDR-E-MI-26116 |
| MNDR | hsa-miR-200b-3p | Cardiovascular disease | MNDR-E-MI-26117 |
| MNDR | hsa-miR-200b-3p | Lung cancer | MNDR-E-MI-26118 |
| MNDR | hsa-miR-200b-3p | Endometrial cancer | MNDR-E-MI-26119 |
| MNDR | hsa-miR-200b-3p | Parkinson disease | MNDR-E-MI-26120 |
| MNDR | hsa-miR-200b-3p | Basal-like breast cancer | MNDR-E-MI-26121 |
| MNDR | hsa-miR-200b-3p | Cancer | MNDR-E-MI-26122 |
| MNDR | hsa-miR-200b-3p | Thyroid cancer | MNDR-E-MI-26123 |
| MNDR | hsa-miR-200b-3p | Pituitary neoplasms | MNDR-E-MI-26124 |
| MNDR | hsa-miR-200b-3p | Pancreatic cancer | MNDR-E-MI-26125 |
| MNDR | hsa-miR-200b-3p | Melanoma | MNDR-E-MI-26126 |
| MNDR | hsa-miR-200b-3p | Rectum adenocarcinoma | MNDR-E-MI-26127 |
| MNDR | hsa-miR-200b-3p | Nephroblastoma | MNDR-E-MI-26128 |
| MNDR | hsa-miR-200b-3p | Colon cancer | MNDR-E-MI-26129 |
| MNDR | hsa-miR-200b-3p | Ischemic attack transient | MNDR-E-MI-26130 |
| MNDR | hsa-miR-200b-3p | Colon adenocarcinoma | MNDR-E-MI-26131 |
| MNDR | hsa-miR-200b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26132 |
| MNDR | hsa-miR-200b-3p | Familial ovarian cancer | MNDR-E-MI-26133 |
| MNDR | hsa-miR-200b-3p | Acromegaly | MNDR-E-MI-26134 |
| MNDR | hsa-miR-200b-3p | Kidney cancer | MNDR-E-MI-26135 |
| MNDR | hsa-miR-200b-3p | Endometrial adenocarcinoma | MNDR-E-MI-26136 |
| MNDR | hsa-miR-200b-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-26137 |
| MNDR | hsa-miR-200b-3p | Endometriosis | MNDR-E-MI-26138 |
| MNDR | hsa-miR-200b-3p | Carcinoma ductal breast | MNDR-E-MI-26139 |
| MNDR | hsa-miR-200b-3p | Glioblastoma | MNDR-E-MI-26140 |
| MNDR | hsa-miR-200b-3p | Astrocytoma | MNDR-E-MI-26141 |
| MNDR | hsa-miR-200b-3p | Glioma | MNDR-E-MI-26142 |
| MNDR | hsa-miR-200b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-26143 |
| MNDR | hsa-miR-200b-3p | Breast carcinoma | MNDR-E-MI-26144 |
| MNDR | hsa-miR-200b-3p | Uterine cancer | MNDR-E-MI-26145 |
| MNDR | hsa-miR-200b-3p | Cervical adenocarcinoma | MNDR-E-MI-26146 |
| MNDR | hsa-miR-200b-3p | Gastric adenocarcinoma | MNDR-E-MI-26147 |
| MNDR | hsa-miR-200b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26148 |
| MNDR | hsa-miR-200b-3p | Pituitary adenoma | MNDR-E-MI-26149 |
| MNDR | hsa-miR-200b-3p | Lung squamous cell carcinoma | MNDR-E-MI-26150 |
| MNDR | hsa-miR-200b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-26151 |
| MNDR | hsa-miR-200b-3p | Lung adenocarcinoma | MNDR-E-MI-26152 |
| MNDR | hsa-miR-200b-3p | Ovarian carcinoma | MNDR-E-MI-26153 |
| MNDR | hsa-miR-200b-3p | Bladder urothelial carcinoma | MNDR-E-MI-26154 |
| MNDR | hsa-miR-200b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-26155 |
| MNDR | hsa-miR-200b-3p | Carcinoma renal cell | MNDR-E-MI-26156 |
| MNDR | hsa-miR-200b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26157 |
| MNDR | hsa-miR-200b-3p | Clear cell renal cell carcinoma | MNDR-E-MI-26158 |
| MNDR | hsa-miR-200b-3p | Allergic rhinitis | MNDR-E-MI-26159 |
| MNDR | hsa-miR-200b-3p | Biliary tract cancer | MNDR-E-MI-26160 |
| MNDR | hsa-miR-200b-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-26161 |
| MNDR | hsa-miR-200b-3p | Cholangiocarcinoma | MNDR-E-MI-26162 |
| MNDR | hsa-miR-200b-3p | Lung small cell carcinoma | MNDR-E-MI-26163 |
| MNDR | hsa-miR-200b-3p | Gastric carcinoma | MNDR-E-MI-26164 |
| MNDR | hsa-miR-200b-3p | Testicular germ cell cancer | MNDR-E-MI-26165 |
| MNDR | hsa-miR-200b-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-26166 |
| MNDR | hsa-miR-200b-3p | Adenoma | MNDR-E-MI-26167 |
| MNDR | hsa-miR-200b-3p | Breast invasive carcinoma | MNDR-E-MI-26168 |
| MNDR | hsa-miR-200b-3p | Hepatocellular carcinoma | MNDR-E-MI-26169 |
| MNDR | hsa-miR-200b-3p | Familiar ovarian carcinoma | MNDR-E-MI-26170 |
| MNDR | hsa-miR-200b-3p | B-cell lymphoma | MNDR-E-MI-26171 |
| MNDR | hsa-miR-200b-3p | Malignant pleural mesothelioma | MNDR-E-MI-26172 |
| MNDR | hsa-miR-200b-3p | Periodontitis | MNDR-E-MI-26173 |
| MNDR | hsa-miR-200b-3p | Hodgkin lymphoma | MNDR-E-MI-26174 |
| MNDR | hsa-miR-200b-3p | Ulcerative colitis | MNDR-E-MI-26175 |
| MNDR | hsa-miR-200b-3p | Burkitt lymphoma | MNDR-E-MI-26176 |
| MNDR | hsa-miR-200b-3p | Crohn disease | MNDR-E-MI-26177 |
| MNDR | hsa-miR-200b-3p | Skin cutaneous melanoma | MNDR-E-MI-26178 |
| MNDR | hsa-miR-200b-3p | Skin melanoma | MNDR-E-MI-26179 |
| MNDR | hsa-miR-200b-3p | Acute myelogenous leukemia | MNDR-E-MI-26180 |
| MNDR | hsa-miR-200b-3p | Colorectal cancer | MNDR-E-MI-26181 |
| MNDR | hsa-miR-200b-3p | Multiple myeloma | MNDR-E-MI-26182 |
| MNDR | hsa-miR-200b-3p | Type 1 diabetes mellitus | MNDR-E-MI-26183 |
| MNDR | hsa-miR-200b-3p | Ovarian epithelial cancer | MNDR-E-MI-26184 |
| MNDR | hsa-miR-200b-3p | Autoimmune diseases | MNDR-E-MI-26185 |
| MNDR | hsa-miR-200b-3p | Graft vs host disease | MNDR-E-MI-26186 |
| MNDR | hsa-miR-200b-3p | Prostatic neoplasms | MNDR-E-MI-26187 |
| MNDR | hsa-miR-200b-3p | Chronic pain | MNDR-E-MI-26188 |
| MNDR | hsa-miR-200b-3p | Breast cancer her3+ negative | MNDR-E-MI-26189 |
| MNDR | hsa-miR-200b-3p | Cholestatic liver injury | MNDR-E-MI-26190 |
| MNDR | hsa-miR-200b-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-26191 |
| MNDR | hsa-miR-200b-3p | Tubulovillous adenoma | MNDR-E-MI-26192 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAM12 | Homo sapiens | RR00040359 |
TOP